EVO evotec.com: Quick Liquidity Indicator

Evotec SE (EVO) is attracting leading data experts and biochemists to scale its contract work volume while maintaining a stable headcount. The company is implementing artificial intelligence to accelerate molecule discovery, optimizing partners' laboratory testing costs. This price chart with the 2.19 indicator illustrates the dynamics of a business that generates revenue through long-term R&D agreements and milestone payments from pharmaceutical behemoths.

EVO: Evotec AG Intermediate Liquidity Ratio 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for evotec.com (EVO)

- share price and expert price forecast:

Stock Price Evotec Corp|EVO - Analyst Consensus Forecast

- company stock capitalization data:

Market Valuation Evotec Corp|EVO - Value Adjusted for Debt and Cash

- book capitalization indicators:

Accounting Value per Share Evotec|EVO - Total Net Assets|Market Capitalization to Book Value Ratio evotec.com|EVO - Company Assets

- business debt structure and liquidity details:

- earnings and valuation multiples information:

EVO - Company Net Income

Fundamental company valuation:Evotec SE

Regular payments from long-term biotech test outsourcing support the solvency of Evotec SE (EVO), creating a stable cash flow. By analyzing a historical snapshot of immediate liquidity, an investor assesses the company's ability to meet its obligations without liquidating inventory, relying solely on cash and accounts receivable, which distinguishes efficient capital management from excessive idle capacity.

Competitors of Evotec SE (EVO)